Penumbra (PEN) EBIT Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -3.76% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 8.39% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 1.70% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 25.88% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 7.13% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 34.83% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 75.54% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -2.70% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | -24.91% |
| 10 | Penumbra | 12.52 Bn | 11.91 Bn | 253.41 Mn | 68.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.39% |
| Dec 31, 2025 | 130.56% |
| Sep 30, 2025 | 107.91% |
| Jun 30, 2025 | 566.24% |
| Mar 31, 2025 | 128.77% |
| Dec 31, 2024 | 45.30% |
| Sep 30, 2024 | 59.10% |
| Jun 30, 2024 | -114.37% |
| Mar 31, 2024 | -3.49% |
| Dec 31, 2023 | 180.52% |
| Sep 30, 2023 | 37.97% |
| Jun 30, 2023 | 44.44% |
| Mar 31, 2023 | 135.90% |
| Dec 31, 2022 | -22.98% |
| Sep 30, 2022 | -25.18% |
| Jun 30, 2022 | -26.22% |
| Mar 31, 2022 | -33.19% |
| Dec 31, 2021 | -100.05% |
| Sep 30, 2021 | 34.28% |
| Jun 30, 2021 | 3.57% |
| Mar 31, 2021 | 49.31% |
| Dec 31, 2020 | -34.86% |
| Sep 30, 2020 | -215.86% |
| Jun 30, 2020 | -136.87% |
| Mar 31, 2020 | 31.97% |
| Dec 31, 2019 | 123.63% |
| Sep 30, 2019 | 125.85% |
| Jun 30, 2019 | 176.36% |
| Mar 31, 2019 | 82.49% |
| Dec 31, 2018 | 54.17% |
| Sep 30, 2018 | -126.08% |
| Jun 30, 2018 | 64.29% |
| Mar 31, 2018 | 0.46% |
| Dec 31, 2017 | 128.78% |
| Sep 30, 2017 | 29.98% |
| Jun 30, 2017 | -27.33% |
| Mar 31, 2017 | -28.41% |